Authors:
CUTLER NR
JHEE SS
CYRUS P
BIEBER F
TANPIENGCO P
SRAMEK JJ
GULANSKI B
Citation: Nr. Cutler et al., SAFETY AND TOLERABILITY OF METRIFONATE IN PATIENTS WITH ALZHEIMERS-DISEASE - RESULTS OF A MAXIMUM TOLERATED DOSE STUDY, Life sciences, 62(16), 1998, pp. 1433-1441
Authors:
TOMBAUGH TN
WHITE RF
CYRUS P
KRENGEL M
ROSE F
Citation: Tn. Tombaugh et al., VALIDATION OF THE TEST FOR MEMORY MALINGERING (TOMM) WITH COGNITIVELYINTACT AND NEUROLOGICALLY IMPAIRED SUBJECTS, Archives of clinical neuropsychology, 12(4), 1997, pp. 418-418
Authors:
CYRUS P
ORAZEM J
RUZICKA B
MAS J
BIEBER F
GULANSKI B
Citation: P. Cyrus et al., METRIFONATE TREATMENT OF ALZHEIMERS-DISEASE (AD) - INFLUENCE OF DEMOGRAPHIC CHARACTERISTICS, Journal of the American Geriatrics Society, 45(9), 1997, pp. 40-40
Authors:
KRENGEL M
WHITE RF
DIAMOND R
LETZ R
CYRUS P
DURSO R
Citation: M. Krengel et al., A COMPARISON OF NES2 AND TRADITIONAL NEUROPSYCHOLOGICAL TESTS IN A NEUROLOGIC PATIENT SAMPLE, Neurotoxicology and teratology, 18(4), 1996, pp. 435-439
Authors:
VENTURINI M
MICHELOTTI A
DELMASTRO L
GALLO L
CAMINO F
GARRONE O
TIBALDI C
MOLEA N
BELLINA RC
PRONZATO P
CYRUS P
VINKE J
TESTORE F
GUELFI M
LIONETTO R
BRUZZI P
CONTE PF
ROSSO R
Citation: M. Venturini et al., MULTICENTER RANDOMIZED CONTROLLED CLINICAL-TRIAL TO EVALUATE CARDIOPROTECTION OF DEXRAZOXANE VERSUS NO CARDIOPROTECTION IN WOMEN RECEIVING EPIRUBICIN CHEMOTHERAPY FOR ADVANCED BREAST-CANCER, Journal of clinical oncology, 14(12), 1996, pp. 3112-3120